These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35835873)

  • 61. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
    Liu C; Sun L; Xu J; Zhao Y
    World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
    Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
    Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): a large cohort study of 2770 patients.
    Lin KY; Chen QJ; Tang SC; Lin ZW; Zhang JX; Zheng SM; Li YT; Wang XM; Lu Q; Fu J; Guo LB; Zheng LF; You PH; Wu MM; Lin KC; Zhou WP; Yang T; Zeng YY
    BMC Cancer; 2023 Dec; 23(1):1190. PubMed ID: 38053048
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria.
    Ho SY; Liu PH; Hsu CY; Hsia CY; Huang YH; Su CW; Lei HJ; Lee RC; Hou MC; Huo TI
    Dig Dis Sci; 2020 Feb; 65(2):658-667. PubMed ID: 31659612
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
    Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
    J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.
    Yang B; Zheng B; Yang M; Zeng Z; Yang F; Pu J; Li C; Liao Z
    Hepatol Int; 2018 Sep; 12(5):417-428. PubMed ID: 30073454
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular Carcinoma.
    Suh SW; Choi YS
    Yonsei Med J; 2017 Jul; 58(4):737-742. PubMed ID: 28540985
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis.
    Guo Z; Zhong JH; Jiang JH; Zhang J; Xiang BD; Li LQ
    Ann Surg Oncol; 2014 Sep; 21(9):3069-76. PubMed ID: 24728740
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Preoperative C-reactive protein/albumin ratio to predict mortality and recurrence of patients with hepatocellular carcinoma after curative resection.
    Ren Y; Fan X; Chen G; Zhou D; Lin H; Cai X
    Med Clin (Barc); 2019 Sep; 153(5):183-190. PubMed ID: 30606506
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Azemoto R; Shinozaki M; Yoshikawa M; Yokosuka O
    PLoS One; 2015; 10(4):e0125244. PubMed ID: 25919025
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma.
    Gómez-Rodríguez R; Romero-Gutiérrez M; Artaza-Varasa T; González-Frutos C; Ciampi-Dopazo JJ; de-la-Cruz-Pérez G; Sánchez-Ruano JJ
    Rev Esp Enferm Dig; 2012 Jun; 104(6):298-304. PubMed ID: 22738699
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
    Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
    World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
    Kuo MJ; Mo LR; Chen CL
    BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
    Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
    J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study.
    Xue T; Le F; Chen R; Xie X; Zhang L; Ge N; Chen Y; Wang Y; Zhang B; Ye S; Ren Z
    Med Oncol; 2015 Mar; 32(3):64. PubMed ID: 25682389
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model.
    Kim BK; Shim JH; Kim SU; Park JY; Kim DY; Ahn SH; Kim KM; Lim YS; Han KH; Lee HC
    Liver Int; 2016 Jan; 36(1):92-9. PubMed ID: 25950442
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
    World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score.
    Park Y; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Park YE; Park JH; Lee YI; Yun HR; Han KH
    Liver Int; 2016 Jan; 36(1):100-7. PubMed ID: 26013186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.